[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-conserving-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-conserving-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,73,103,131,158,186,207,224,246],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100620077","a-novel-intraoperative-fluorescence-guided-system-for-evaluating-margins-during-breast-conserving-surgery-for-breast-cancer-100620077",false,"NCT07352930","A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer","A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologically confirmed diagnosis of primary invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component. Acceptable diagnostic methods include core needle biopsy or fine-needle aspiration biopsy.\n2. Female, age ≥ 18 years.\n3. Scheduled to undergo breast-conserving surgery for the malignant breast lesion.\n4. Willing and able to comply with the study procedures and follow-up.\n5. Has provided written informed consent.\n6. No other uncontrolled serious medical conditions aside from the cancer diagnosis (see Exclusion Criteria for details).\n7. Adequate organ and bone marrow function, defined as:\n\n   * White blood cell count \\> 3,000\u002FμL\n   * Platelet count \\> 75,000\u002FμL\n   * Total bilirubin ≤ institutional upper limit of normal (ULN)\n   * AST (SGOT) \u002F ALT (SGPT) \\\u003C 2.5 × institutional ULN\n   * Serum creatinine ≤ 1.5 mg\u002FdL, OR creatinine clearance \\> 60 mL\u002Fmin\u002F1.73 m² (for participants with serum creatinine levels above institutional ULN)\n8. ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Suspected pregnancy.\n3. Prior injection of ICG or other fluorescent dyes for sentinel lymph node mapping on the day of surgery, before the planned lumpectomy cavity scan with the study device.\n4. Unresolved adverse events from previous medications or diagnostic agents.\n5. Uncontrolled hypertension, defined as persistent systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg. Patients with known hypertension must be stable on medication within these limits.\n6. History of allergy to any oral or intravenous contrast agent.\n7. Uncontrolled comorbidities, including but not limited to:\n\n   * Active infection\n   * Symptomatic congestive heart failure\n   * Unstable angina pectoris\n   * Cardiac arrhythmia\n   * Hospitalization for COPD or asthma within the past 12 months\n   * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n8. Any condition where, in the investigator's judgment, participation would not be in the best interest of the participant.\n9. Planned re-excision lumpectomy due to positive margins from a prior surgery performed before enrollment.\n10. Prior surgical history in the ipsilateral breast, including breast cancer surgery, mastectomy, breast reconstruction, or implant placement.","FEMALE","18 Years",{"count":19,"type":20},172,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if a novel intraoperative fluorescence-guided system (EndoSCell Scanner) can help surgeons more accurately remove all cancerous tissue during breast-conserving surgery in female patients aged 18 years or older, with primary breast cancer. The main questions it aims to answer are:\n\n* Does the use of the EndoSCell Scanner system lower the rate of secondary surgeries needed due to positive cancer margins after the initial operation?\n* How accurate is the EndoSCell Scanner system in detecting residual cancer cells on the walls of the surgical cavity during the operation?\n\nResearchers will compare the surgical outcomes using the EndoSCell Scanner guidance to the expected outcomes from standard surgical practice without this technology to see if the system is effective.\n\nParticipants will:\n\n* Receive their planned breast-conserving surgery (lumpectomy).\n* Have their surgical cavity scanned with the EndoSCell Scanner device after the main tumor is removed.\n* Have additional tissue removed from the cavity wall if the scanner indicates a potential cancer residue.",[26],"Breast-Conserving Surgery",[28,29,30],"Intraoperative Imaging","Fluorescence-Guided Surgery","Positive Margins","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2026-04-01",{"date":39,"type":20},"2027-03-31",{"name":41,"class":42},"Guangdong Provincial People's Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100607208","intraoperative-ultrasound-guided-vs-wire-guided-vs-magnetic-seed-guided-breast-conserving-surgery-for-non-palpable-tumors-100607208","NCT07185568","IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors","IntraOperative UltraSound Guided Versus Wire Guided Versus Magnetic Seed Guided Breast-conserving Surgery for Non-palpable Tumors.The MANOLA Study Multi-center, Randomized, Open-label Clinical Trial","MANOLA","Inclusion Criteria:\n\n* Patients with non-palpable breast cancer candidate for breast-conserving surgery;\n* Female patients;\n* Patients aged ≥ 18 years;\n* Patients with histologic diagnosis of cT1-T2 invasive BC or ductal carcinoma in situ;\n* Patients amenable for BCS after neoadjuvant chemotherapy;\n* Patients who are able to give informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or lactation;\n* Patients with locally advanced disease or metastatic disease;\n* Patients with palpable breast carcinoma;\n* Patients candidate for mastectomy;\n* Patients who are unable to give informed consent\n* Patients candidate for mastectomy.",{"count":53,"type":20},1302,[23],"This is a multi-center, randomized, open-label clinical trial that will enroll 1302 adult patients with non-palpable breast lesions. Participant eligible for the study will be randomized in a 1:1:1 ratio to one of the pre-surgery lesion localization: IOUS HydroMark™ (experimental arm A), magnetic Sirius Pintuition Seed® (experimental arm B) and the wire localization technique (control arm). The randomization will be stratified by lesion type (solid non-palpable (type B); non-solid non-palpable (e.g., microcalcification clusters, architectural distortive areas) (type C); post-NACT residual lesions (type D), and clinical center.",[57,26],"Breast Cancer",[59,60,61],"IntraOperative UltraSound guided","Wire guided","Magnetic Seed guided","NOT_YET_RECRUITING","2026-06-22",{"date":65,"type":35},"2026-06-23",{"date":67,"type":20},"2026-08-04",{"date":69,"type":20},"2027-12-31",{"name":71,"class":42},"Istituto Oncologico Veneto IRCCS",5,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100444813","phase-3-long-term-outcomes-of-lidocaine-infusions-for-post-operative-pain-lolipop-trial-100444813","NCT05072314","Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","LOLIPOP","Inclusion Criteria:\n\n* Consenting adult female patients (≥18 years) undergoing mastectomy (unilateral or bilateral) or breast conserving surgery (unilateral or bilateral) for the primary excision of confirmed or suspected primary breast cancer under general anaesthesia (including those with simultaneous insertion of tissue expanders or implants)\\*. \\* this specifically excludes patients undergoing surgery for locoregional recurrence\n* American Society of Anaesthesiologist (ASA) physical scale 1-3\n\nExclusion Criteria:\n\n* Mastectomy or breast conserving surgery with add on procedures e.g laparoscopic salpingectomy\n* Where surgery is being performed for locoregional recurrence of breast cancer\n* Pre-existing pain at site of surgery, axilla, ipsilateral side of chest wall or the ipsilateral upper arm (at diagnosis prior to any tumor locating procedures)\n* Re-excision procedures where the margins at the index surgery have been deemed insufficient\n* When immediate autologous reconstruction surgery is planned\n* Where delayed autologous reconstruction surgery on the operative breast within one year is planned\n* Planned use of regional analgesia infusions\n* Impaired cognition\n* Pregnant or lactating females\n* Transgender patients\n* Known metastatic disease\n* History of anaphylaxis, sensitivity or known contraindication to lidocaine (or other amide local anaesthetic agents e.g. other amide local anaesthetic agents: ropivacaine, bupivacaine, mepivacaine, prilocaine, etidocaine), including patients with porphyria or methaemoglobinaemia\n* History of epilepsy\n* Baseline heart rate \\< 50 bpm or systolic blood pressure \\< 100mmHg.\n* Acute coronary event in the last three months\n* Cardiac conduction abnormalities, including; Atrial fibrillation, Heart block (all degrees), Bundle Branch Block or Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome. A preoperative Electrocardiogram (ECG) is not mandatory, unless clinically indicated\n* Abnormal serum potassium concentration (based upon site laboratory reference ranges)\n* Active liver disease e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes)\n* Medications within the last 7 days which are known \u002F suspected to slow lidocaine metabolism (amiodarone, beta blockers, cimetidine, fluoroquinolones, fluvoxamine, imidazoles, macrolides, verapamil, HIV drugs)\n* Cardiac Failure (any documented heart failure at peroperative assessment or GP records)\n* Severe Renal Failure (Creatinine Clearance of less than 30ml\u002Fmin or dialysis dependent)\n* Co-administration of lidocaine within 24 hours prior to surgery for other reasons (e.g. lidocaine patches",{"count":81,"type":20},4300,[83],"PHASE3","The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.",[57,86,87,88],"Breast Cancer Female","Breast Conserving Surgery","Mastectomy",[90,91,92],"Anaesthesia","Local Anaesthesia","Chronic Post Surgical Pain","2026-03-22",{"date":95,"type":35},"2026-03-25",{"date":97,"type":35},"2022-07-27",{"date":99,"type":20},"2028-07",{"name":101,"class":42},"Monash University",47,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":43},"100608789","feasibility-study-for-the-sira-1000-sira-rfa-electrosurgical-device-as-an-adjunct-to-breast-conserving-surgery-100608789","NCT07206121","Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery","A Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery","Inclusion Criteria:\n\n1. Biologic female\n2. 50 years of age and older\n3. Confirmed diagnosis of breast cancer:\n\n   1. Infiltrating ductal carcinoma\n   2. ER\u002FPR+Her2neu-\n   3. Grade I, II, or III\n4. Unicentric, unilateral tumor size ≤ 3cm\n5. Tumor location ≥ 2 cm from skin and other structures\n6. Zubrod Performance Status of 0, 1, or 2\n7. No palpable lymphadenopathy\n8. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Neoadjuvant chemotherapy\n3. Cardiac arrhythmia\n4. Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device\n5. Current or history of breast implants\n6. Multi-centric or bilateral breast cancer\n7. Diffuse microcalcifications\n8. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter the outcomes under study\n9. Has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.","50 Years",{"count":5,"type":20},[23],"This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.",[57,115,116,117,118],"Breast-conserving Surgery","Breast Cancer - Infiltrating Ductal Carcinoma","ER\u002FPR+Her2neu","Grade I, II, III",[120],"Breast conserving surgery for breast cancer.","2026-02-09",{"date":123,"type":35},"2026-02-11",{"date":125,"type":20},"2026-02-10",{"date":127,"type":20},"2032-02-06",{"name":129,"class":130},"Innoblative Designs, Inc.","INDUSTRY",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":137,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100595222","comparative-research-on-the-accuracy-of-margin-interpretation-in-breast-conserving-surgery-for-breast-cancer-cell-microscopic-imaging-and-standard-frozen-pathology-100595222","NCT07029646","Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen Pathology","Inclusion Criteria:\n\n* Aged between 18 and 70 years old;\n* Clinical or imaging showed a single lesion with no evidence of distant metastasis;\n* No invasion of the skin, subcutaneous tissue, pectoralis major muscle, and nipple-areola complex;\n* Breast cancer patients who are willing to undergo breast-conserving surgery;\n* Subjects voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Allergic constitution;\n* Chest wall or skin invasion, locally advanced breast cancer;\n* Extensive axillary lymph node metastasis (stage ⅢB and above);\n* Patients with severe complications (such as organ dysfunction, immunodeficiency) and poor general condition;\n* Unable to accept general anesthesia or surgical treatment;\n* Participating in other clinical studies that may affect this trial;\n* Patients who cannot send frozen pathology and paraffin pathology specimens for examination during surgery.","ALL","70 Years",{"count":140,"type":20},167,[23],"The goal of this clinical trial is to assess whether cell microscopic imaging can accurately determine the tumor-free status of surgical margins in breast cancer patients undergoing breast-conserving surgery. This study involves female patients aged 18-70 years with breast cancer who are candidates for breast-conserving surgery. The main question it aims to answer is:\n\n\\- Can cell microscopic imaging provide accurate intraoperative assessment of surgical margins compared to standard frozen pathology?\n\nResearchers will compare the results of cell microscopic imaging to those of standard frozen pathology and paraffin pathology to see if the new imaging technology can effectively and quickly determine whether surgical margins are free of cancer cells.\n\nParticipants will:\n\n* Undergo breast-conserving surgery with standard pathological assessments.\n* Have their surgical margins evaluated using cell microscopic imaging during the operation.\n* Be monitored for postoperative recovery at regular intervals (2 weeks, 3 months, 6 months, and 12 months) after the surgery.",[26,144,145],"Breast Carcinoma","Margins in the Specimen",[26,57,147,148],"Margins","microscope","2025-06-11",{"date":151,"type":35},"2025-06-19",{"date":153,"type":20},"2025-07-01",{"date":155,"type":20},"2026-12-31",{"name":157,"class":42},"Peking University Cancer Hospital & Institute",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":138,"enrollmentInfo":166,"targetDuration":168,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100561666","single-port-endoscopic-breast-conserving-surgery-100561666","NCT06593132","Single Port Endoscopic Breast Conserving Surgery","Prospective Clinical Study of Single Port Endoscopic Breast Conserving Surgery or Open Breast Conserving Surgery for Early Breast Cancer","Inclusion Criteria:\n\n1. Breast cancer confirmed by pathology；\n2. Tumor \\\u003C5 cm, TNM stage 0-II；\n3. Single Port Endoscopic or traditional open surgery; (4)20 to 70 years old female patients.\n\nExclusion Criteria:\n\n1. Bilateral breast cancer;\n2. Reconstruction after breast conserving surgery ;\n3. Basic information is not complete；\n4. Breast conserving surgery was converted to modified radical resection or subcutaneous adenoidectomy.","20 Years",{"count":167,"type":20},200,"6 Months","OBSERVATIONAL","The center plans to carry out a prospective clinical study of single hole total endoscopic breast conserving surgery for early breast cancer compared with open breast conserving surgery, to provide high-level evidence-based medical evidence for the development of endoscopic breast conserving surgery for early breast cancer.",[87,172],"Endoscopic Surgery",[174,175,176],"breast conserving surgery","single port endoscopic","early breast cancer","2024-09-10",{"date":179,"type":35},"2024-09-19",{"date":181,"type":35},"2023-01-01",{"date":183,"type":20},"2025-06",{"name":185,"class":42},"Ren,Yu",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":43},"100503649","efficacy-and-accuracy-of-combined-localization-versus-single-localization-in-non-palpable-breast-cancer-after-neoadjuvant-therapy-100503649","NCT05838001","Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy","Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neo-adjuvant Therapy : a Prospective Randomized Control Trial.","Inclusion Criteria:\n\n1. female patients, age≥18 year\n2. A score of ≥ 2 on the Eastern Cooperative Oncology Group scale\n3. Patients pathologically diagnosed with breast cancer by core-needle biopsy, received neoadjuvant treatment and the lesion becomes non-palpable before enrollment.\n4. Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery\n\nExclusion Criteria:\n\n1. Inflammatory breast cancer or Paget's disease\n2. Breast deformities and other conditions that impact breast conservation success rate\n3. Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded.\n4. Pregnancy or lactation\n5. Patients with hook-wire, radioactive 125I seed or other localization techniques in the breast cancer lesions before enrollment\n6. Patients with stage IV diseases or unresectable lesions in either breast\n7. Patients combined with other diseases that may affect survival\n8. Patients with multicentric breast cancer lesions or lesions \\> 5 cm in diameter on imaging examinations\n9. Patients who have previously undergone radical mastectomy for ipsilateral breast cancer or chest wall radiotherapy\n10. Patients with history of ipsilateral breast cancer radical mastectomy or chest wall radiotherapy",{"count":194,"type":20},110,[23],"The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs. combined breast tissue markers in localizing non-palpable breast cancer.",[57,115],"2024-07-01",{"date":200,"type":35},"2024-07-03",{"date":202,"type":35},"2023-02-16",{"date":204,"type":20},"2025-12-01",{"name":206,"class":42},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":43},"100500530","efficacy-and-accuracy-of-combined-localization-versus-single-localization-in-non-palpable-breast-cancer-100500530","NCT05797454","Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer","Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer: a Prospective Randomized Control Trial.","Inclusion Criteria:\n\n1. female patients, age≥18 year\n2. A score of ≥ 2 on the Eastern Cooperative Oncology Group scale\n3. Patients pathologically diagnosed with untreated breast cancer by core-needle biopsy, with histologically confirmed non-palpable in situ cancer, including pleomorphic lobular carcinoma in situ or invasive non-palpable breast cancer that required localization\n4. Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery.\n\nExclusion criteria:\n\n1. Inflammatory breast cancer or Paget's disease\n2. Breast deformities and other conditions that impact breast conservation success rate\n3. Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded\n4. Pregnancy or lactation\n5. Patients with hookwire, radioactive 125I seed or other localization techniques in the breast cancer lesions before enrollment\n6. Patients with stage IV diseases or unresectable lesions in either breast\n7. Patients combined with other diseases that may affect survival\n8. Patients with multicentric breast cancer lesions or lesions \\> 5 cm in diameter on imaging examinations\n9. Patients who have previously undergone radical mastectomy for ipsilateral breast cancer or chest wall radiotherapy",{"count":215,"type":20},170,[23],"The standard method for localizing non-palpable breast cancer is currently preoperative wire-guided localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of wire vs. combined breast tissue markers in localizing non-palpable breast cancer.",[57,115],{"date":200,"type":35},{"date":221,"type":35},"2023-02-17",{"date":204,"type":20},{"name":206,"class":42},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":43},"100552583","intra-surgery-high-resolution-specimen-petct-imager-for-margin-assessment-in-early-stage-breast-cancer-100552583","NCT06474975","Intra-SURGerY High-resolution Specimen PET\u002FCT Imager for Margin Assessment in Early-stage Breast Cancer","SURGYPET: Intra-SURGerY High-resolution Specimen PET\u002FCT Imager for Margin Assessment in Early-stage Breast Cancer as Compared to Gross Pathology: a Prospective Non-inferiority Analysis","SURGYPET","Inclusion Criteria:\n\n* females with an age over 18 years;\n* confirmed breast cancer with indication to undergo BCS (stage I-II with tumor ≤2.5 in greatest dimension);\n* vacuum-assisted core breast biopsy is allowed for non-invasive tumors only;\n* able to understand treatment protocol and informed consent form;\n* estimated by the investigator to be compliant for study participation.\n\nExclusion Criteria:\n\n* general or local contra-indication for BCS;\n* previous breast surgery;\n* inflammatory breast cancer;\n* radiotherapy of the ipsilateral breast;\n* vacuum-assisted core breast biopsy for all patients with invasive tumors (vacuum-assisted core breast biopsy is allowed for patients with non-invasive tumors as long as the residual tumor size on mammogram is at least 1.0 cm);\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year;\n* active bacterial, viral or fungal infection.",{"count":233,"type":20},150,[23],"This study is a diagnostic open-label, prospective, single-arm non-inferiority clinical trial.\n\nThe primary endpoint is the accuracy to detect positive invasive margins in invasive ductal carcinoma (IDC) patients by high-resolution specimen Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) imaging.",[57,115],"2024-06-20",{"date":239,"type":35},"2024-06-26",{"date":241,"type":20},"2024-07",{"date":243,"type":20},"2026-07",{"name":245,"class":42},"European Institute of Oncology",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":257,"conditions":258,"keywords":259,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":43},"100551708","tumour-localisation-with-magnetic-clip-before-neoadjuvant-chemotherapy-100551708","NCT06463600","Tumour Localisation With Magnetic Clip Before Neoadjuvant Chemotherapy.","Tumour Localisation With Magnetic Clip Before Neoadjuvant Chemotherapy. A Randomised Pilot Feasibility Study: MagLocal 1.0","MagLocal","Inclusion Criteria:\n\n1. Age above 18 years\n2. Planned for preoperative chemotherapy before breast cancer surgery\n3. Planned breast conserving surgery with targeted axillary dissection or sentinel lymph node biopsy using magnetic technique\n4. SLN-biopsy with magnetic tracer or targeted axillary dissection using magnetic tracer and Magseed\n5. Signed and dated written informed consent before the start of specific protocol procedures\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding\n2. Iron overload disease\n3. Known hypersensitivity to iron or dextran compounds\n4. Inability to understand given information and give informed consent or undergo study procedures\n5. Planned MRI control for tumour response during chemotherapy",{"count":255,"type":20},44,[23],"The feasibility of the use of magnetic clips for tumour localisation before preoperative chemotherapy in combination with superparamagnetic iron oxide nanoparticles (SPIO) as tracer for sentinel lymph node (SLN) detection and in combination with a magnetic clip in the index lymph node metastasis is studied.",[87],[260,261,262,263,264],"Breast cancer","Tumour localisation","Magnetic clip","magnetic tracer","Preoperative chemotherapy","2024-06-15",{"date":267,"type":35},"2024-06-18",{"date":269,"type":35},"2024-02-01",{"date":271,"type":20},"2025-12-31",{"name":273,"class":42},"Sahlgrenska University Hospital"]